Skip to main content
Pediatric AML: Gemtuzumab ozogamicin prior to allo-HCT increases risk for veno-occlusive disease
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Pediatric AML: Gemtuzumab ozogamicin prior to allo-HCT increases risk for veno-occlusive disease
User login
Username
Password
Reset your password
concept
Lead
score
Acute Leukemia
1
1
Specialty
Lead
score
Hematology-Oncology
1
1